Is Ozempic Linked to Gastroparesis? What the Evidence Shows

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Pharmacovigilance

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication is causing gastroparesis—a condition where the stomach empties too slowly. For decades, pharmacovigilance systems have tracked adverse drug reactions to inform clinical practice, and recent reports have raised specific concerns about GLP-1 receptor agonists. This guide examines the current evidence on Ozempic and gastroparesis, including FDA warnings and what patients should know.

Bridging to Ozempic and Gastroparesis

This transition necessitates moving from a broad health information paradigm to a targeted examination of exposure-related risks. Specifically, the question of whether Ozempic exposure is associated with an increased risk of gastroparesis—a condition of delayed gastric emptying—represents a critical pivot. This inquiry bridges the legacy of general health education with a focused clinical concern: understanding the potential consequences of sustained pharmacological exposure on digestive motility. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Its clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, with symptoms persisting for at least three months. The condition can be idiopathic or secondary to diabetes, surgery, or medications. In the context of Ozempic (semaglutide), a GLP-1 receptor agonist used for type 2 diabetes, gastrointestinal adverse effects are well-documented, raising questions about a potential causal link to gastroparesis.

Ozempic Pharmacology and Reported Adverse Effects

Ozempic works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, slows gastric emptying, and promotes satiety. This pharmacological action inherently affects gastrointestinal motility. According to the FDA-approved label, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which are consistent with the known effects of GLP-1 agonists on gastric motility.

Mechanistic Pathways Linking Ozempic to Gastroparesis

The mechanistic link between Ozempic and gastroparesis is biologically plausible. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, a mechanism that contributes to their glucose-lowering and weight-loss effects. Prolonged or excessive delay in gastric emptying can lead to symptoms indistinguishable from gastroparesis, such as nausea, vomiting, and early satiety. While the label does not explicitly list gastroparesis as an adverse reaction, the reported gastrointestinal effects—including dyspepsia, gastroesophageal reflux disease, and gastritis—suggest a spectrum of upper gastrointestinal dysfunction. The absence of a specific gastroparesis diagnosis in clinical trials may reflect under-recognition or misclassification, as symptoms overlap with common adverse effects. Additionally, serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but these are distinct from gastroparesis.

Risk Anchors: Adequacy of Warnings, Causation Considerations, and Timeline

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The FDA label does not include a specific warning for gastroparesis, but it does caution about gastrointestinal adverse reactions, which are common and can lead to discontinuation. For affected patients, establishing causation requires careful evaluation. Key considerations include: (1) the temporal relationship between Ozempic initiation and symptom onset, (2) exclusion of other causes (e.g., diabetic gastroparesis, idiopathic disease), and (3) symptom improvement upon drug discontinuation. The timeline between exposure and documented harm is variable. In clinical trials, gastrointestinal symptoms often emerged during dose escalation, suggesting a rapid onset for some patients. However, chronic use may lead to persistent gastric dysmotility. The lack of specific gastroparesis data in the label limits the ability to quantify risk precisely. Patients with pre-existing gastrointestinal conditions may be at higher risk, and the dose-dependent nature of adverse effects (e.g., higher rates with 2 mg vs 1 mg) supports a causal gradient.

Conclusion

While Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological effect on gastric emptying and the high incidence of gastrointestinal adverse reactions provide a plausible mechanistic link. The evidence from clinical trials shows a dose-dependent increase in symptoms such as dyspepsia, nausea, and vomiting, which overlap with gastroparesis. For patients experiencing severe or persistent gastrointestinal symptoms, clinicians should consider the possibility of drug-induced gastroparesis and evaluate accordingly. The adequacy of current warnings may be insufficient for patients who develop this condition, highlighting the need for heightened awareness and further research.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction. Symptoms include early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, with symptoms persisting for at least three months.

Does Ozempic cause gastroparesis?

The FDA label does not explicitly list gastroparesis as an adverse reaction, but Ozempic's mechanism of action slows gastric emptying, and clinical trials show a dose-dependent increase in gastrointestinal symptoms such as dyspepsia, nausea, and vomiting, which overlap with gastroparesis. A causal link is biologically plausible, but further research is needed.

What gastrointestinal side effects are reported with Ozempic?

According to the FDA label, gastrointestinal adverse reactions occurred in up to 36.4% of patients on Ozempic 1 mg, including nausea, vomiting, diarrhea, dyspepsia, eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

How can I determine if my gastroparesis is caused by Ozempic?

Establishing causation requires evaluating the temporal relationship between Ozempic initiation and symptom onset, excluding other causes (e.g., diabetic gastroparesis), and observing symptom improvement upon drug discontinuation. Consult your healthcare provider for a thorough assessment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Ozempic

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.